A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
Status:
Completed
Trial end date:
2006-06-29
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50
mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.